Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

Publication Title

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Authors

Katherine Sanchez
Shu-Ching Chang, Medical Data Research Center, Providence Health & Services, Portland, OR, USAFollow
Isaac Kim
Maritza Martel
Yaping Wu, Pathology, Providence Portland Medical CenterFollow
William L. Redmond, Earle A Chiles Research InstituteFollow
Zhaoyu Sun
Dottie Waddell
Deborah R. Laxague
Brady BernardFollow
Monil Shah
Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.Follow
David B. Page

Document Type

Article

Publication Date

5-25-2020

Clinical Institute

Cancer

Specialty

Oncology

Specialty

Earle A. Chiles Research Institute

Recommended Citation

Sanchez, Katherine; Chang, Shu-Ching; Kim, Isaac; Martel, Maritza; Wu, Yaping; Redmond, William L.; Sun, Zhaoyu; Waddell, Dottie; Laxague, Deborah R.; Bernard, Brady; Shah, Monil; Urba, Walter; and Page, David B., "Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC)." (2020). Articles, Abstracts, and Reports. 3760.
https://digitalcommons.providence.org/publications/3760